Air pollution-linked blood changes detected years before lung cancer diagnosis
medicalxpress - A new study, published Tuesday in Nature Communications, found measurable changes in people's blood associated with exposure to air pollution and the subsequent development of lung cancer. The findings provide promising clues that could help shape future …
AI Summary: New analyses link long‑term air pollution exposure to distinct blood metabolic and biomarker changes that appear years before lung cancer diagnosis, suggesting a window for earlier detection. The work identifies candidate pathways tying inhaled pollutants to carcinogenic processes and proposes blood‑based signals for future screening or risk stratification.
CMS ends Medicaid, CHIP funding for gender-affirming care for minors
fiercehealthcare - The Trump administration has finalized a rule that would pull funding gender-affirming care for minors from Medicaid and the Children's Health Insurance Program.
AI Summary: CMS announced a policy change ending Medicaid and CHIP funding for gender‑affirming care for minors, effectively narrowing federal support and prompting immediate concern from providers, families and advocacy groups. The move is expected to produce a patchwork of state responses, legal challenges and disrupted care pathways as clinicians and health systems adjust to suddenly constrained coverage.
Lucy Davis Reveals Incurable Stage 4 Breast Cancer: Diagnosis, Bone Metastases, and What We Know
oncodaily - British actress Lucy Davis, best known for playing Dawn Tinsley in the original UK version of The Office, has revealed that she has been living with stage 4 breast cancer […]
AI Summary: Actor Lucy Davis disclosed a diagnosis of incurable stage‑4 breast cancer with bone metastases, using her platform to raise awareness about prognosis, screening and self‑examination. Her candid account underscores the reality of metastatic disease and encourages people to pay attention to subtle changes, not just lumps.
Wolfgang Miesbach: JAMA Updates Rules on AI Use in Medical Publishing
oncodaily - Wolfgang Miesbach, Head of the Department of Haemostaseology and the Haemophilia Center of Medical Clinic 2 and Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn: “JAMA […]
AI Summary: JAMA updated its authorship and disclosure policies to clarify acceptable uses of generative AI in medical publishing, tightening requirements and banning unacknowledged AI contributions. The guidance aims to preserve scientific integrity while acknowledging AI’s growing role — yes, the journal is telling computers to behave themselves.
Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records
Katie Adams / medcitynews - Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year.The post Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records …
AI Summary: A ransomware attack on a health IT vendor exposed nearly four million patient records, prompting urgent security reviews and fresh scrutiny of vendor controls. The incident highlights systemic vulnerabilities in healthcare data protections, spurred regulatory attention and calls for tighter oversight across third‑party technology providers.
Providence to completely exit insurance business after Medicare Advantage deal falls through
Jakob Emerson / beckershospitalreview - Providence Health Plan will completely shut down after it was unable to reach a deal with a national insurer to operate its Medicare Advantage business. “We are in discussion with regulators about this development and the broader wind-down of Providence’s…
AI Summary: Providence announced it will completely exit the insurance business after a proposed Medicare Advantage transaction fell apart, triggering a wind‑down of its health plan. The move comes amid a broader operational turnaround that has shown sizable improvements but forces the system to refocus on core provider operations and financial stabilization.
- Providence $400M turnaround and CFO appointment (4)
- Providence Health Plan exits after Medicare Advantage deal (4)
- All Other Stories
Providence $400M turnaround and CFO appointment
Providence Health Plan exits after Medicare Advantage deal
All Other Stories
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.
Health advocacy group sues AMA to make billing codes public
Rebecca Pifer Parduhn / healthcaredive - PatientRightsAdvocate.org is challenging the doctor’s association’s copyright of the current procedural terminology, or CPT, system. Use of the codes is required by law, and that means they should be freely available, per the suit.
AI Summary: A health advocacy group has taken the American Medical Association to court seeking public access to the CPT billing code system, arguing that proprietary control reduces transparency around medical billing and pricing. The legal action challenges AMA’s copyright and could force broader disclosure of codes used across U.S. healthcare.
Luigi Mangione pleads guilty in federal case over murder of UnitedHealthcare CEO Brian Thompson
fiercehealthcare - The man accused of murdering UnitedHealthcare CEO Brian Thompson has pleaded guilty in the federal trial against him, per media reports.
AI Summary: Luigi Mangione has admitted guilt in the fatal shooting of UnitedHealthcare CEO Brian Thompson, culminating in a federal plea that closes a bloody chapter and opens a messy one. The killing intensified public fury toward insurers and sparked investor litigation alleging $237 million in suspicious insider stock sales tied to the aftermath.
Appeals Court Sides with Providers in No Surprises Act Pay Dispute
Katie Adams / medcitynews - A court ruling struck down key parts of how regulators calculate the No Surprises Act’s qualifying payment amount, siding with the Texas Medical Association’s argument that the formula has historically favored payers in arbitration. The post Appeals Court…
AI Summary: An appeals court has sided with providers, striking down the government’s method for calculating the No Surprises Act’s qualifying payment amounts and rejecting parts of the current QPA rule. The decision upends how out-of-network payment disputes are arbitrated, hands leverage back to providers, and injects fresh uncertainty into insurer-provider billing battles.
FDA advisers to weigh cancer blood test
Ella Jeffries / beckershospitalreview - The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet Sept. 23 to discuss and vote on Grail’s premarket approval application for its Galleri blood test, according to a notice published Aug. 10 in the Federal R…
AI Summary: FDA advisors are set to review a multi-cancer early-detection blood test, weighing evidence on accuracy, clinical utility, and how to handle follow-up diagnostics. Regulators must decide whether the test meets approval standards for broad screening, balancing potential earlier cancer detection against risks of false positives, overdiagnosis, and costly downstream workups.
WHO says Congo's Ebola outbreak is on track to surpass the deadliest one in history
medicalxpress - The ongoing Ebola outbreak in Congo is on track to surpass the deadliest one in history that killed over 11,000 people, the head of the World Health Organization said Wednesday.
AI Summary: The World Health Organization warns Congo’s Ebola outbreak is moving faster than any previous one, with cases and deaths climbing rapidly and the toll surpassing early grim milestones. Investigations suggest transmission began months before detection, authorities scramble to contain spread along river routes and in communities while public-health teams race to stem transmission.
- Record surge in cases and deaths (8)
- Vaccine trials and containment challenges (4)
- WHO warnings, timeline, and global urgency (5)
- All Other Stories
Record surge in cases and deaths
Vaccine trials and containment challenges
WHO warnings, timeline, and global urgency
All Other Stories
Flesh‑eating bacteria are devouring limbs in warming waters worldwide—here's how to protect yourself
medicalxpress - Flesh-eating bacteria sound like the premise of a bad horror movie, but they're a growing—and potentially fatal—threat to people in the U.S. and beyond.
AI Summary: Health authorities report a rise in Vibrio and related "flesh‑eating" bacterial infections as warming coastal waters expand suitable habitat. Areas along the Gulf Coast, including Louisiana, have seen increased hospitalizations and deaths, prompting advisories urging wound-care vigilance, cautious seafood handling, and avoidance of seawater exposure for susceptible individuals.
Cassidy, Sanders press DOJ on former Steward CEO’s contempt referral
Sy Mukherjee / healthcaredive - The Senate referred the former Ralph de la Torre, Steward Health Care’s former CEO, for possible prosecution nearly two years ago after he defied a congressional subpoena. Now, two Senators are asking for an update.
AI Summary: Lawmakers have formally urged the Justice Department for clarity and action on a contempt referral tied to the former CEO of Steward Health Care. The congressional push seeks to determine whether prosecutorial steps will follow alleged noncompliance with court orders, elevating scrutiny of corporate accountability and enforcement in healthcare governance.
Hinge Health expands into gastrointestinal care with $105M acquisition
Rebecca Pifer Parduhn / healthcaredive - Hinge is purchasing Cylinder Health in a “logical extension” of the San Francisco-based company’s business, one analyst commented.
AI Summary: Hinge Health has moved into gastrointestinal care through a $105 million acquisition, signaling expansion beyond musculoskeletal digital health. Market observers and insiders offer contrasting views: some praise the strategic diversification and patient‑access potential, others question integration risks and whether digital models translate cleanly into GI service lines.
The AI boom could strengthen Epic's position, health system execs say. Here's where startups and health tech vendors can still win
fiercehealthcare - Clinician-facing AI, imaging AI, patient AI assistants, discharge and care transitions and revenue cycle AI are the categories where health systems are most willing to look beyond Epic, executives said.
AI Summary: Health system executives warn that the surge in AI interest is strengthening incumbent EHR vendors, notably Epic, which can bundle AI features into existing workflows at scale. Startups face an uphill battle unless they target niche integration gaps, interoperability wins or demonstrable ROI — in short, cleverness and agility beat nostalgia for disruption.
- Connecting care: interoperability, prior auth and data exchange (5)
- Epic's AI offensive: UGM rollouts, tools and tokenomics (9)
- Health systems scaling AI: governance, ROI and safety (7)
- Startups and vendors: where to pivot in an Epic world (7)
- All Other Stories
Connecting care: interoperability, prior auth and data exchange
Epic's AI offensive: UGM rollouts, tools and tokenomics
Health systems scaling AI: governance, ROI and safety
Startups and vendors: where to pivot in an Epic world
All Other Stories
AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
How a Deadly Superbug Tricks the Immune System to Survive in Hair Follicles
discovermagazine - Learn how Candida auris takes advantage of the skin’s immune response to stay put inside hair follicles.
AI Summary: Researchers show that Candida auris can persist in hair follicles by rewiring local skin immune responses, creating a hidden reservoir that helps the fungus survive disinfection and spread in healthcare settings. The finding explains persistent colonization and suggests new diagnostic and decolonization strategies focused on follicular niches — because apparently this pathogen likes a good hairdo.
Senate Confirms Dr. Erica Schwartz as C.D.C. Director
Apoorva Mandavilli / nytimes - Dr. Schwartz, a deputy surgeon general in the first Trump administration, has publicly supported childhood vaccines.
AI Summary: Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention after a high-profile nomination process. She will assume leadership of the agency responsible for national disease prevention and public health preparedness, steering CDC policy and operations amid ongoing public‑health challenges and scrutiny of federal responses.
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)